Lilly presents phase II data on abemaciclib in early-stage breast cancer
Eli Lilly has announced that the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, met its primary endpoint of reducing expression of Ki67, a biomarker of...